Asset Details
Do you wish to reserve the book?
The tumorigenicity of human embryonic and induced pluripotent stem cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The tumorigenicity of human embryonic and induced pluripotent stem cells
Do you wish to request the book?
The tumorigenicity of human embryonic and induced pluripotent stem cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The tumorigenicity of human embryonic and induced pluripotent stem cells
2011
Overview
Key Points
Human embryonic stem cells (HESCs) share cellular and molecular phenotypes with tumour cells and cancer cell lines. When injected into immunodeficient mice, HESCs form teratomas. The tumorigenicity of HESCs is a major hurdle, which must be confronted before the achievements from this field of research can be safely translated into the clinic.
Sharing with HESCs their basic properties of self-renewal and pluripotency, human induced pluripotent stem cells (HiPSCs) also share their tumorigenic traits. However, HESCs and HiPSCs are not identical, and a rapidly accumulating body of work suggests considerable differences between these two pluripotent cell types.
The transcription factors commonly used for reprogramming somatic cells into HiPSCs (
OCT4
,
SOX2
,
MYC
and krupple-like factor 4 (
KLF4
)) are highly expressed in various types of cancer. HiPSCs are commonly derived using integrating vectors, thus creating a risk for genetic alterations and for reactivation of the reprogramming factors at later stages.
HiPSCs can acquire chromosomal aberrations, even more readily than HESCs. These can result from their somatic cells of origin, reprogramming stress and during culture adaptation. Aneuploidy of pluripotent stem cells has been suggested to increase their tumorigenicity.
Epigenetic differences between HESCs and HiPSCs also affect their tumorigenicity. The reprogramming process is often accompanied by epigenetic alterations. The epigenetic 'memory' of the cells might also contribute to their tumorigenicity.
Self-renewal is important for the tumorigenic traits of HESCs and HiPSCs, and cell cycle-related genes are crucial for an efficient reprogramming process. These genes are also involved in the genomic instability that characterizes pluripotent cells.
Owing to genetic and epigenetic causes, HiPSCs are more tumorigenic than HESCs, and harbour a risk for the development of teratocarcinomas and possibly somatic tumours.
In order to develop safe HESC- and HiPSC-based treatments, the tumorigenicity hurdle must be overcome. Three general strategies to cope with this risk have been suggested: terminal differentiation or complete elimination of residual pluripotent stem cells from culture; interfering with tumour-progression genes to prevent tumour formation from the residual pluripotent cells; and tumour detection and elimination after its initial formation in the patient's body.
The unique ability of human pluripotent stem cells to self-renew and to differentiate into cells of the three germ layers makes them an invaluable tool for the future of regenerative medicine and tumorigenic research. It was assumed that human induced pluripotent stem cells (HiPSCs) would behave like their embryonic counterparts in respect to their tumorigenicity, but a rapidly accumulating body of evidence suggests that there are important differences.
The unique abilities of human pluripotent stem cells to self-renew and to differentiate into cells of the three germ layers make them an invaluable tool for the future of regenerative medicine. However, the same properties also make them tumorigenic, and therefore hinder their clinical application. Hence, the tumorigenicity of human embryonic stem cells (HESCs) has been extensively studied. Until recently, it was assumed that human induced pluripotent stem cells (HiPSCs) would behave like their embryonic counterparts in respect to their tumorigenicity. However, a rapidly accumulating body of evidence suggests that there are important genetic and epigenetic differences between these two cell types, which seem to influence their tumorigenicity.
Publisher
Nature Publishing Group UK,Nature Publishing Group
